In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $101.13 in the prior trading day, Exact Sciences Corp (NASDAQ: EXAS) closed at $101.45, up 0.32%. In other words, the price has increased by $0.32 from its previous closing price. On the day, 6.4 million shares were traded. EXAS stock price reached its highest trading level at $101.61 during the session, while it also had its lowest trading level at $101.1159.
Ratios:
Our goal is to gain a better understanding of EXAS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 77.92. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 1.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when ORVILLE JACOB A sold 5,000 shares for $75.00 per share. The transaction valued at 375,000 led to the insider holds 23,237 shares of the business.
Herriott James sold 1,000 shares of EXAS for $70,000 on Nov 19 ’25. The SVP, General Counsel & Sec now owns 11,585 shares after completing the transaction at $70.00 per share. On Nov 19 ’25, another insider, ORVILLE JACOB A, who serves as the Officer of the company, bought 5,000 shares for $75.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 19251742720 and an Enterprise Value of 20753842176. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.25 while its Price-to-Book (P/B) ratio in mrq is 7.68. Its current Enterprise Value per Revenue stands at 6.734 whereas that against EBITDA is 192.203.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.35, which has changed by 0.63418174 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $101.87, while it has fallen to a 52-week low of $38.81. The 50-Day Moving Average of the stock is 54.31%, while the 200-Day Moving Average is calculated to be 89.52%.
Shares Statistics:
The stock has traded on average 4.50M shares per day over the past 3-months and 15035000 shares per day over the last 10 days, according to various share statistics. A total of 189.45M shares are outstanding, with a floating share count of 186.41M. Insiders hold about 1.62% of the company’s shares, while institutions hold 94.62% stake in the company. Shares short for EXAS as of 1763078400 were 7359833 with a Short Ratio of 1.64, compared to 1760486400 on 7968887. Therefore, it implies a Short% of Shares Outstanding of 7359833 and a Short% of Float of 4.44.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Exact Sciences Corp (EXAS).The consensus estimate for the next quarter is $0.1, with high estimates of $0.24 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.56 and $0.04 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is $1.12, with 8.0 analysts recommending between $1.52 and $0.63.
Revenue Estimates
20 analysts predict $860.75M in revenue for. The current quarter. It ranges from a high estimate of $864.8M to a low estimate of $855.9M. As of. The current estimate, Exact Sciences Corp’s year-ago sales were $713.42MFor the next quarter, 20 analysts are estimating revenue of $831.95M. There is a high estimate of $854.03M for the next quarter, whereas the lowest estimate is $774.68M.
A total of 21 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $3.23B, while the lowest revenue estimate was $3.22B, resulting in an average revenue estimate of $3.23B. In the same quarter a year ago, actual revenue was $2.76BBased on 21 analysts’ estimates, the company’s revenue will be $3.67B in the next fiscal year. The high estimate is $3.76B and the low estimate is $3.48B.
